Left Atrial Myxoma

Comprehensive Clinical Guide: Left Atrial Myxoma

1. Introduction and Overview

A Left Atrial Myxoma (LAM) is the most common primary cardiac tumor in adults, accounting for approximately 50% of all primary cardiac neoplasms. While histologically benign, its clinical behavior is often malignant due to its location, potential for intracardiac obstruction, and risk of systemic embolization. These tumors typically arise from the interatrial septum, specifically the region of the fossa ovalis.

Though non-cancerous, a Left Atrial Myxoma is a "medical emergency in waiting." Its ability to mimic mitral valve disease, infective endocarditis, or systemic connective tissue disorders makes it a diagnostic chameleon. Understanding the nuances of this entity is critical for cardiologists, cardiac surgeons, and primary care physicians alike.

2. Etiology and Pathophysiology

The precise cellular origin of myxomas remains a subject of intense investigation. Current consensus suggests they arise from multipotent mesenchymal cells capable of both neural and endocrine differentiation.

Pathogenesis

• Location: 75% arise in the left atrium, 20% in the right atrium, and the remainder in the ventricles.
• Attachment: The majority are pedunculated, attached to the interatrial septum by a thin stalk.
• Growth: They grow as gelatinous, friable masses. Their friability is the primary driver of embolic risk.
• Genetics: While most are sporadic, approximately 10% are associated with Carney Complex, an autosomal dominant disorder characterized by myxomas, spotty skin pigmentation (lentiginosis), and endocrine overactivity (e.g., Cushing syndrome).

Histological Features

• Myxoma Cells: Polygonal cells embedded in an abundant acid mucopolysaccharide stroma.
• Vascularity: Often demonstrate prominent neovascularization, which contributes to the tumor's friability.
• Surface: Covered by endothelium, though ulceration and thrombus formation are common.

3. Clinical Presentation and Staging

The clinical presentation of LAM is often described by the "triad of symptoms": Obstructive, Embolic, and Constitutional.

The Symptomatic Triad

Staging and Classification

There is no formal TNM staging for benign cardiac myxomas. Instead, clinicians utilize a Functional Impact Scale:

1. Grade I (Asymptomatic): Incidental finding on routine imaging.
2. Grade II (Mild/Intermittent): Positional dyspnea or occasional palpitations.
3. Grade III (Symptomatic): Chronic heart failure symptoms, recurrent embolic events.
4. Grade IV (Critical): Acute obstruction, syncope, or massive systemic embolization requiring emergency intervention.

4. Differential Diagnosis

Because LAM mimics many conditions, clinicians must maintain a high index of suspicion.

• Mitral Valve Stenosis: LAM can obstruct the mitral orifice, causing symptoms identical to rheumatic mitral stenosis.
• Infective Endocarditis: Both present with fever, weight loss, and embolic phenomena.
• Cardiac Thrombus: Usually associated with atrial fibrillation or dilated cardiomyopathy; thrombi are typically mural rather than pedunculated.
• Other Cardiac Tumors: Lipoma, rhabdomyoma, or cardiac sarcoma (which is rarer but more aggressive).

5. Key Diagnostic Tests

The gold standard for diagnosis is non-invasive imaging.

Transthoracic Echocardiogram (TTE)

The first-line screening tool. It provides excellent visualization of the mass, its attachment point, and its impact on hemodynamics.

Transesophageal Echocardiogram (TEE)

The "Gold Standard." TEE offers superior resolution, allowing the surgeon to see the stalk attachment, the mobility of the tumor, and the presence of any secondary thrombi.

Cardiac MRI (CMR)

Highly recommended for tissue characterization. CMR can differentiate between a myxoma, a thrombus, and a malignant sarcoma by assessing gadolinium enhancement patterns.

Coronary Angiography

Often performed pre-operatively in patients over 40 to assess for co-existing coronary artery disease and to evaluate the tumor's blood supply (tumor blush).

6. Surgical Intervention and Long-Term Prognosis

Surgical Management

The treatment of choice is surgical excision. Because of the risk of embolization, surgery is usually performed shortly after diagnosis.
* Technique: Wide excision of the stalk attachment is performed to prevent recurrence.
* Cardiopulmonary Bypass: Essential for safe resection.
* Technique Note: Surgeons must be careful not to manipulate the heart excessively to avoid dislodging fragments during cannulation.

Long-Term Prognosis

• Recurrence: Low (1-3% for sporadic cases). Recurrence is higher (up to 20%) in patients with Carney Complex.
• Survival: Excellent. Most patients experience immediate resolution of constitutional and obstructive symptoms post-operatively.
• Follow-up: Annual echocardiograms are recommended for the first 3–5 years post-surgery.

7. Risks and Contraindications

• Embolic Risk: The highest risk associated with LAM is the fragmentation of the tumor, leading to systemic embolization.
• Surgical Contraindications: There are no absolute contraindications to surgery, as the risk of sudden death from valvular obstruction outweighs surgical risks. However, severe comorbidities may necessitate a high-risk surgical team.
• Anti-coagulation: Generally not recommended unless there is a co-existing atrial thrombus, as it does not shrink the tumor and may increase bleeding risk.

8. Massive FAQ Section

1. Is a Left Atrial Myxoma considered cancer?

No. It is a benign (non-cancerous) tumor. However, it is clinically "malignant" in behavior because it can cause severe obstruction and stroke.

2. What is the "tumor plop"?

The "tumor plop" is an extra heart sound heard during auscultation. It occurs when the tumor moves into the mitral valve orifice during diastole, creating a low-frequency sound as it hits the valve leaflets.

3. Can a myxoma go away on its own?

No. Myxomas are physical masses of tissue. They do not regress and must be surgically removed.

4. Why do myxoma patients have fevers?

Myxomas produce high levels of Interleukin-6 (IL-6), a cytokine that triggers an inflammatory response in the body, leading to fever, weight loss, and elevated C-reactive protein (CRP).

5. Is there a genetic link?

Most are sporadic. However, in families with Carney Complex, myxomas are part of a genetic syndrome caused by mutations in the PRKAR1A gene.

6. What happens if a myxoma is left untreated?

Untreated LAM leads to progressive heart failure, sudden death due to obstruction of the mitral valve, or fatal stroke due to embolization.

7. How long is the recovery after surgery?

Most patients spend 1–2 days in the ICU and 4–7 days in the hospital. Full recovery typically takes 6–8 weeks.

8. Does the tumor grow back?

Recurrence is rare for sporadic tumors, but follow-up is essential. If it does recur, it is usually due to incomplete resection of the stalk.

9. Can I exercise with a myxoma?

No. Physical exertion increases blood flow and heart rate, which can increase the risk of the tumor obstructing the mitral valve or breaking off (embolizing).

10. Are there any medications to shrink the tumor?

Currently, there is no medical or pharmacological therapy that can dissolve or shrink a cardiac myxoma. Surgical resection is the only definitive treatment.

9. Summary Table: Clinical Snapshot

10. Clinical Conclusion

The Left Atrial Myxoma serves as a quintessential example of why clinical history and high-resolution imaging must remain the cornerstone of cardiovascular medicine. While the tumor is histologically benign, its capacity for systemic destruction demands a swift, aggressive, and highly specialized surgical approach. Early detection via echocardiography remains the most effective tool in preventing the catastrophic complications—namely stroke and sudden cardiac death—that define the natural history of this condition.

Medical professionals should maintain a high index of suspicion in any patient presenting with unexplained constitutional symptoms, new-onset mitral valve murmurs, or embolic events of unknown origin. Once identified, surgical consultation should be prioritized as the standard of care to ensure the best possible patient outcome.